CAJ | 학술논문

目的评价多西他赛联合奈达铂治疗老年妇女复发性上皮性卵巢癌的疗效和安全性.方法 42例复发性上皮性卵巢癌老年患者应用多西他赛联合奈达铂化疗方案,多西他赛60～70mg/m2,第1天静脉滴注,奈达铂70～80mg/m2,第2天静脉滴注,3周重复,采用实体肿瘤治疗疗效评估标准(RECIST)和血清CA125水平进行疗效评估,不良反应依据WHO抗癌药物毒性表现及分级标准进行评价.结果 42例老年患者中有4例患者因病情进展,完成2个疗程后改用其他方案,其余患者均完成4～6个疗程化疗.42例患者中完全缓解18例(42.9％),部分缓解10例(23.8％),病情稳定6例(14.3％),疾病进展8例(19.0％),中位疾病无进展生存时间7个月,有效率为66.7％(28/42).不良反应发生率前3位依次为脱发、恶心呕吐、白细胞减少,患者均可接受或通过药物治疗缓解.结论多西他赛联合奈达铂方案治疗老年妇女铂类敏感及耐药复发性上皮性卵巢癌均有较好的疗效,不良反应发生率相对较低,安全性高,耐受性好.
목적 평개다서타새연합내체박치료노년부녀복발성상피성란소암적료효화안전성.방법 42례복발성상피성란소암노년환자응용다서타새연합내체박화료방안,다서타새60～70mg/m2,제1천정맥적주,내체박70～80mg/m2,제2천정맥적주,3주중복,채용실체종류치료료효평고표준(RECIST)화혈청CA125수평진행료효평고,불량반응의거WHO항암약물독성표현급분급표준진행평개.결과 42례노년환자중유4례환자인병정진전,완성2개료정후개용기타방안,기여환자균완성4～6개료정화료.42례환자중완전완해18례(42.9％),부분완해10례(23.8％),병정은정6례(14.3％),질병진전8례(19.0％),중위질병무진전생존시간7개월,유효솔위66.7％(28/42).불량반응발생솔전3위의차위탈발、악심구토、백세포감소,환자균가접수혹통과약물치료완해.결론 다서타새연합내체박방안치료노년부녀박류민감급내약복발성상피성란소암균유교호적료효,불량반응발생솔상대교저,안전성고,내수성호.
Objective To evaluate the efficacy and safety of concomitant docetaxal (DTX) and nedaplatin (NDP) therapy for recurrent epithelial ovarian cancer in elderly women.Methods Totally 42 elderly patients with histologically confirmed recurrent epithelial ovarian cancer received chemotherapy with DTX combined with NDP.DTX with the dose of 60-70 mg/m2 was administered intravenously on day 1,followed by NDP with the dose of 70-80 mg/m2 given intravenously on day 2.The treatment was repeated every 3 weeks.The efficacy was evaluated according to response evaluation criteria in solid tumors (RECIST) and serum CA125 level.Adverse reactions were assessed according to performance and standard criteria in toxicity of anticancer agents of WTO.Results 4 patients were switched to other chemotherapy strategies due to progression of disease after 2 courses of treament,and the other patients completed 4 to 6 courses.Among 42 patients,18 cases (42.9％)showed complete remission,10 cases (23.8％) showed partial remission,6 cases (14.3％) were in stable conditions,and 8 cases (19.0％) progressed to severe disease.The median progression-free survival (PFS) time was 7 months,and the efficacy rate (complete and partial remission) was 66.7％(28/42).The main adverse effects were alopecia,nausea and vomit,and leucopenia.Patients could get remission by receiving drug therapy.Conclusions Docetaxel plus nedaplatin therapy has a good therapeutic effect with low incidence of adverse reactions,high safety and well tolerance in elderly platinum-sensitive women and in those with platinum-resistant recurrent epithelial ovarian cancer.